

## DAFTAR PUSTAKA

Ecke TH, Schlechte HH, Schiemenz K, et al. TP53 gene mutations in prostate cancer progression. *Anticancer Res.* 2010;30(5):1579-1586

Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. *Mol Nutr Food Res.* 2009;53(2):171–84

Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. *Clin Cancer Res.* 2014;20(4):890–903

Mack PC, Chi SG, Meyers FJ, Stewart SL, DeVere White RW, Gumerlock PH. Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade. *Prostate.* 1998;34(2):145-151

Lin X et al. Assessment of biochemical recurrence of prostate cancer (Review). *Int J of Oncology.* 2019. 55:1194-1212

Mottet N, Bellmunt J, Representative EBP, et al. Prostate Cancer EAU Guidelines 2017. *Eur Urol.* 2017

Sun, J., Li, S., Wang, F. et al. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis. *BMC Med Genet* 20, 191 (2019) doi:10.1186/s12881-019-0923-7

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer. *Nat Rev Urol.* 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review. PubMed PMID: 29460925

Campbell-Walsh. Campbell-Walsh Urology - 4 Volume Set  
[11E][2016][UnitedVRG][PDF].pdf. 2015

Umbas R, Hardjowijoto S, Mochtar CA, Safriadi F, Djatisoesanto W, Soedarso MA, et al. Panduan Penatalaksanaan kanker prostat 2011. Ikatan Ahli Urologi Indonesia. 2011

Rosa M, Chopra HK, Sahoo S. Fine needle aspiration biopsy diagnosis of metastatic prostate carcinoma to inguinal lymph node. *Diagn Cytopathol* [Internet]. 2007 Sep 1;35(9):565–7. Available from: <https://doi.org/10.1002/dc.20693>

K. HK, E. MJ, K. TM, A. ST. Random Systematic Versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate. *J Urol* [Internet]. 1989 Jul 1;142(1):71–4. Available from: [https://doi.org/10.1016/S0022-5347\(17\)38664-0](https://doi.org/10.1016/S0022-5347(17)38664-0)

Cooperberg MR, Lubeck DP, Meng M V, Mehta SS, Carroll PR. The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management. *J Clin Oncol* [Internet]. 2004 Jun 1;22(11):2141–9. Available from: <https://doi.org/10.1200/JCO.2004.10.062>

Master VA, Chi T, Simko JP et al. The independent impact of extended pattern biopsy on. Vol. 1793, prostate cancer stage migration. *J Urol*. 2005. 174:1789-1793

Boccon-Gibod LM, Dumonceau O, Toubanc M, Ravery V, Boccon-Gibod LA. Micro-Focal Prostate Cancer: A Comparison of Biopsy and Radical Prostatectomy Specimen Features. *Eur Urol* [Internet]. 2005 Dec 1;48(6):895–9. Available from: <https://doi.org/10.1016/j.eururo.2005.04.033>

Jradi MA, Dridi M, Teyeb M, Mohamed MOS, Khiary R, Ghazzi S, et al. The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer. *Can Urol Assoc J* [Internet]. 2010 Apr;4(2):100–4. Available from:

<https://www.ncbi.nlm.nih.gov/pubmed/20368891>

V. MM, P. EE, Janeen D, R. CP, null null. Impact of Increased Number of Biopsies on the Nature of Prostate Cancer Identified. J Urol [Internet]. 2006 Jul 1;176(1):63–9. Available from: [https://doi.org/10.1016/S0022-5347\(06\)00493-9](https://doi.org/10.1016/S0022-5347(06)00493-9)

Epstein JI. An Update of the Gleason Grading System. JURO. 2010;183(2):433–40.

Goodrich DW, Wang NP, Qian YW, Lee EYHP, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. 1991;67(2):293–302

Rodrigues DN, Casiraghi N, Romanel A, Crespo M, Miranda S, Rescigno P, et al. Rb1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(2):687–97

Ku S, Rosario S, Wnag Y. Rb1 and Trp53 prostate cancer lineage plasticity, metastasis. Science (80- ). 2017;(January)

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019;76(1):89–97

Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118(17):4280–9.

Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

Velcheti V, Karnik S, Bardot SF, Prakash O. Pathogenesis of Prostate Cancer : Lessons from Basic Research Pathogenesis of Prostate Cancer : Lessons from Basic Research. 2008;1(January 2014)

Muga S De. KLF6 and TP53 mutations are a rare event in prostate cancer : distinguishing between Taq polymerase artifacts and true mutations. 2008;1470–8  
John R.Giudicessi, BA.Michael J.Ackerman. 2013. 基因的改变 NIH Public Access. Bone. 2008;23(1):1–7

Lopez DS, Peskoe SB, Joshu CE, Dobs A, Kanarek N, Nelson WG, et al. concentrations in US adolescent males. 2013;24(4)

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU Guidelines on Prostate Cancer . Part 1 : Screening , Diagnosis , and Treatment of Clinically Localised Disease. Eur Urol [Internet]. 2011;59(1):61–71. Available from: <http://dx.doi.org/10.1016/j.eururo.2010.10.039>

Knipper S, Graefen M. Treatment options for localized prostate cancer. Onkologe. 2019;25(3):279–88

Tan W, Liu B, Qu S, Liang G, Luo W, Gong C. MicroRNAs and cancer: Key paradigms in molecular therapy (Review). Oncol Lett. 2018;15(3):2735–42

Di Leva G, Croce CM. The Role of microRNAs in Cancer. Target Ther Transl Cancer Res. 2015;79:80–8

Su Deng PM. MicroRNAs in Prostate Cancer: Small RNAs with Big Roles. J Clin Cell Immunol. 2015;06(02)

Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: Biomarkers, functions and

therapy. *Trends Mol Med*. 2014;20(8):460–9

Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It's all about diversity. *Semin Cancer Biol*. 2019 Dec;59:66-79. doi: 10.1016/j.semcancer.2019.02.001. Epub 2019 Feb 7. Review. PubMed PMID: 30738865

Rawla P. Epidemiology of Prostate Cancer. *World J Oncol*. 2019;10(2):63-89

Li H, Hodgson E, Walson L, Shukla A, Nelson JJ. Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. *J Cancer Epid*. 2012. 291704

Xiao H et al. Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida. *Am J Mens Health*. 2016. 10(4): 285–295

Borno HT, Cowan JE, Zhao S, Broering JM, Carroll PR, Ryan CJ. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. *Urol Oncol Semin Orig Investig [Internet]*. 2020; Available from: <http://www.sciencedirect.com/science/article/pii/S107814392030332X>